Premium
Rho Kinase Inhibitors: the end of endothelial keratoplasty?
Author(s) -
GICQUEL JJ
Publication year - 2012
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2012.1635.x
Subject(s) - economic shortage , medicine , rho associated protein kinase , ophthalmology , dystrophy , ex vivo , bullous keratopathy , cornea , endothelial stem cell , endothelium , kinase , in vivo , microbiology and biotechnology , pathology , biology , in vitro , biochemistry , linguistics , philosophy , government (linguistics)
The human corneal endothelium shows poor regenerative abilities. In cases of pseudophakic bullous keratopathy or Fuchs’ dystrophy, descemet striping automated keratoplasty brings considerable clinical benefits. However there are still allograft rejections and the shortage of donor corneas is a problem that still needs to be solved. The Rho/Rho kinase (ROCK) inhibitors may help establishing ex vivo endothelial cell cultures and may also give birth to new pharmacological treatments of corneal endothelial dysfunction.